pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 23·1 min read
save

Teladoc expands beyond single-visit model with new service launch

Jul 23, 2026·read at Endpoints ↗Positive

Teladoc, a pioneer in virtual care, originally built its platform around brief, one-time doctor appointments that could be completed without an in-person visit.

The company now says that this single-visit approach no longer meets patient needs and has introduced a new offering that expands the scope of its telehealth services.

The launch signals Teladoc’s shift toward more continuous or integrated care models, aiming to keep pace with evolving expectations in digital health.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Teladoc is moving beyond its single-visit roots with new launch”

read at Endpoints ↗
83 words · retrieved Jul 23
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 55m agoAbbVie claims Phase 3 win for multiple myeloma drug etentamigEndpoints
  • 2h agoHealth tech investors are looking at bigger betsEndpoints
  • 4h agoSummit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialEndpoints
  • 5h agoSuperluminal secures $60M for Phase 1 of genetic obesity drugEndpoints
  • 5h agoGSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfrontEndpoints